Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis  by Barichello, Tatiana et al.
European Journal of Pharmacology 697 (2012) 158–164Contents lists available at SciVerse ScienceDirectEuropean Journal of Pharmacology0014-29
http://d
n Corr
fax: þ5
E-mjournal homepage: www.elsevier.com/locate/ejpharImmunopharmacology and inﬂammationCannabidiol reduces host immune response and prevents cognitive
impairments in Wistar rats submitted to pneumococcal meningitisTatiana Barichello a,n, Renan A. Ceretta a, Jaqueline S. Generoso a, Ana Paula Moreira a,
Lutiana R. Sim ~oes a, Clarissa M. Comimb, Jo~ao Quevedo b, Ma´rcia Carvalho Vilela c,e,
Antonio Waldo Zuardi d, Jose´ A. Crippa d, Antoˆnio Lucio Teixeira e
a Laborato´rio de Microbiologia Experimental e Instituto Nacional de Cieˆncia e Tecnologia Translacional em Medicina, Programa de Po´s-Graduac- ~ao em Cieˆncias da Sau´de,
Universidade do Extremo Sul Catarinense, 88806-000 Criciu´ma, SC, Brazil
b Laborato´rio de Neurocieˆncias e Instituto Nacional de Cieˆncia e Tecnologia Translacional em Medicina, Programa de Po´s-Graduac- ~ao em Cieˆncias da Sau´de,
Universidade do Extremo Sul Catarinense, Criciu´ma, SC, Brazil
c Departamento de Biologia Animal, Universidade Federal de Vic-osa, Vic-osa, MG, Brazil
d Departamento de Neurocieˆncias e Cieˆncias do comportamento da Faculdade de Medicina da Universidade de S ~ao Paulo e Instituto Nacional de Cieˆncia e Tecnologia Translacional
em Medicina (INCT-TM), Ribeir~ao Preto, SP, Brazil
e Laborato´rio de Imunofarmacologia, Departamento de Bioquı´mica e Imunologia, Instituto de Cieˆncias Biolo´gicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazila r t i c l e i n f o
Article history:
Received 22 May 2012
Received in revised form
12 September 2012
Accepted 22 September 2012
Available online 16 October 2012
Keywords:
Streptococcus pneumoniae
Meningitis
Cytokine
Chemokine
Memory
Cannabidiol99 & 2012 Elsevier B.V.
x.doi.org/10.1016/j.ejphar.2012.09.053
esponding author. Tel.: þ55 48 99843615, þ
5 48 34434817.
ail address: tba@unesc.net (T. Barichello).
Open access under the Ea b s t r a c t
Pneumococcal meningitis is a life-threatening disease characterized by an acute infection affecting the
pia matter, arachnoid and subarachnoid space. The intense inﬂammatory response is associated with a
signiﬁcant mortality rate and neurologic sequelae, such as, seizures, sensory-motor deﬁcits and
impairment of learning and memory. The aim of this study was to evaluate the effects of acute and
extended administration of cannabidiol on pro-inﬂammatory cytokines and behavioral parameters in
adult Wistar rats submitted to pneumococcal meningitis. Male Wistar rats underwent a cisterna magna
tap and received either 10 ml of sterile saline as a placebo or an equivalent volume of S. pneumoniae
suspension. Rats subjected to meningitis were treated by intraperitoneal injection with cannabidiol
(2.5, 5, or 10 mg/kg once or daily for 9 days after meningitis induction) or a placebo. Six hours after
meningitis induction, the rats that received one dose were killed and the hippocampus and frontal
cortex were obtained to assess cytokines/chemokine and brain-derived neurotrophic factor levels.
On the 10th day, the rats were submitted to the inhibitory avoidance task. After the task, the animals
were killed and samples from the hippocampus and frontal cortex were obtained. The extended
administration of cannabidiol at different doses reduced the TNF-a level in frontal cortex. Prolonged
treatment with canabidiol, 10 mg/kg, prevented memory impairment in rats with pneumococcal
meningitis. Although descriptive, our results demonstrate that cannabidiol has anti-inﬂammatory
effects in pneumococcal meningitis and prevents cognitive sequel.
& 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Pneumococcal meningitis is a complex and serious central
nervous system (CNS) bacterial-induced inﬂammation, affecting
the pia mater, arachnoid and subarachnoid space (Kim, 2008).
Streptococcus pneumoniae meningitis is associated with a signiﬁcant
mortality rate and persisting neurologic sequelae, such as; seizures,
sensory-motor deﬁcits and impairment of learning and memory in
up to 30% of surviving patients (Grimwood et al., 2000; Grandgirard
et al., 2007; Hoogman et al., 2007). Histopathological human data55 48 34312643;
lsevier OA license.showed that the parenchymal damage was caused by an increase of
the intracranial hypertension, interstitial edema and leukocyte
inﬁltration (Nau et al., 1999).
The bacterial replication into subarachnoid space releases
several compounds, such as, lipoteichoic acid, peptidoglycan and
pneumolysin, which are recognized by Toll-like 2 and Toll-like
4 receptors, by antigen-presenting cells (Mook-Kanamori et al.,
2011). Furthermore, meningeal and perivascular macrophages of
CNS play a protective role during bacterial meningitis (Polﬂiet
et al., 2001). They have been found to be capable of sensing
pneumococci and produced pro-inﬂammatory cytokines (Zysk
et al., 1997; Polﬂiet et al., 2001).
Tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b)
and interleukin-6 (IL-6) are the early response cytokine after
pneumococcal meningitis (Ta¨uber and Moser, 1999). For instance,
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cerebrospinal ﬂuid (CSF) in the early course of the disease
(Glimaker et al., 1993). The effects of TNF-a in vivo include fever,
IL-1b production by vascular endothelium cells and leukocyte
activation (Saukkonen et al., 1990). This recruitment of polymor-
phonuclear leukocytes may induce damage not only to the
bacteria but also to the brain (Mook-Kanamori et al., 2011).
In animal model of meningitis the TNF-a, IL-1b, IL-6 and CINC-1
was produced in the ﬁrst hours after induction (Barichello et al.,
2010a). TNF-a administration into CSF, results in similar pathophy-
siological characteristic of bacterial meningitis (Rosenberg et al.,
1995). Furthermore, intrathecal administration of anti-TNF-a anti-
body inhibited leukocytosis and brain edema in rabbit models of
pneumococcal meningitis (Saukkonen et al., 1990). A central role of
the host’s inﬂammatory response in causing cerebral aggravation has
been increasingly accepted (Sellner et al., 2010).
Thus, with an anti-inﬂammatory effect (Zuardi, 2008), canna-
bidiol (CBD) is the main non-psychotropic cannabinoid compo-
nent derived from the Cannabis sativa plant (Izzo et al., 2009), it
has antioxidant, neuroprotective properties and analgesic effects
(Zuardi, 2008). Previous studies demonstrated that CBD reversed
oxidative stress, cognitive impairment and mortality in a sepsis
animal model (Cassol-Jr et al., 2010). It also decreased inﬂammation
in a murine model of lung injury (Ribeiro et al., 2012) and reduced
brain damage in hypoxic-ischemic model (Alvarez et al., 2008).
The aim of the present study was to evaluate the effects of
acute and extended administration of CBD on the release of pro-
inﬂammatory cytokines and behavioral parameters in adult Wistar
rats submitted to pneumococcal meningitis.2. Materials and methods
2.1. Infecting organism
S. pneumoniae (serotype 3) was cultured overnight in 10 ml of
Todd Hewitt broth, diluted in fresh medium and grown to
logarithmic phase. This culture was centrifuged for 10 min at
(5000 g) and resuspended in sterile saline to the concentration of
5109 cfu/ml. The size of the inoculum was conﬁrmed by quantita-
tive cultures (Grandgirard et al., 2007; Barichello et al., 2010a).
2.2. Animal model of meningitis
Adult male Wistar rats (250–350 g body weight), from our
breeding colony were used for the experiments. All procedures were
approved by the Animal Care and Experimentation Committee of
UNESC, Brazil, and followed in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory Animals
(NIH Publications no. 80-23) revised in 1996. All surgical procedures
and bacterial inoculations were performed under anesthesia, con-
sisting of an intraperitoneal administration of ketamine (6.6 mg/kg),
xylazine (0.3 mg/kg), and acepromazine (0.16 mg/kg) (Barichello
et al., 2009). Rats underwent a cisterna magna tap with a 23-
gauge needle. The animals received either 10 ml of sterile saline as a
placebo or an equivalent volume of S. pneumoniae suspension. At the
time of inoculation, animals received ﬂuid replacement and
were subsequently returned to their cages (Irazuzta et al., 2002;
Irazuzta et al., 2008). Meningitis was documented by a quantitative
culture of 5 ml of CSF obtained by puncture of the cisterna magna
(Barichello et al., 2010a).
2.3. Drugs and treatment
CBD (THC-Pharm, Frankfurt, Germany, and STI-Pharm, Brent-
wood, UK) was suspended in polyoxyethylenesorbitan monooleate(Tween 80) 2% saline. The solutions were prepared immediately
before use and were protected from the light during the experi-
mental session. For the treatment, CBD was administered i.p.
immediately after meningitis induction at the doses of 2.5, 5 and
10 mg/kg (Zuardi et al., 2006): with either a single dose at day zero
(for the animals in the acute treatment) or one dose daily for 9 days
(for the animals in the extended treatment). All treatments were
administered in a volume of 1 ml/kg of CBD plus vehicle. For this
experiment we employed n¼5–6 and n¼10 for acute and extended
treatments, respectively in each sub-group. The animals were
divided into ﬁve sub-groups, as described below: sham; meningitis;
meningitisþCBD 2.5 mg/kg; meningitisþCBD 5mg/kg and menin-
gitisþCBD 10 mg/kg.
2.4. Assessment of TNF-a, IL-1b, IL-6 and CINC-1 concentrations
The brain structures, hippocampus, frontal cortex and CSF
were immediately isolated on dry ice and stored at 80 1C for
analyses of the TNF-a, IL-1b, IL-6, and cytokine-induced neutro-
phil chemoattractant (CINC-1) levels. Brieﬂy, hippocampus and
frontal cortex were homogenized in extraction solution contain-
ing aprotinin (100 mg of tissue per 1 ml). The CSF volume from
each animal was adjusted to 100 ml with extraction solution. The
concentration of cytokines/chemokine was determined in hippo-
campus and frontal cortex using commercially available ELISA
assays, following the instructions supplied by the manufacturer
(DuoSet kits, R&D Systems; Minneapolis). The results are shown
in pg/100 mg of tissues in frontal cortex and in hippocampus.
2.5. Assessment of BDNF
Brain-derived neurotrophic factor (BDNF) levels in hippocam-
pus and frontal cortex were measured by anti-BDNF sandwich-
ELISA, according to the manufacturer’s instructions (Chemicon,
USA). Brieﬂy, rat hippocampus and frontal cortex were homo-
genized in phosphate buffer solution (PBS) with 1 mM phenyl-
methylsulfonyl ﬂuoride (PMSF) and 1 mM (EGTA). Microtiter
plates (96-well ﬂat-bottom) were coated for 24 h with the
samples diluted 1:2 in a sample diluent and the standard curve
ranged from 7.8 to 500 pg/ml of BNDF. The plates were then
washed four times with sample diluent and a monoclonal anti-
BNDF rabbit antibody diluted 1:1000 in sample diluent was added
to each well and incubated for 3 h at room temperature. After
washing, a peroxidase conjugated anti-rabbit antibody (diluted
1:1000) was added to each well and incubated at room tempera-
ture for 1 h. After addition of streptavidin-enzyme, substrate and
stop solution, the amount of BDNF was determined by absorbance
in 450 nm and expressed as pg per mg wet tissue protein. The
standard curve demonstrates a direct relationship between Opti-
cal Density (OD) and BDNF concentration. Total protein was
measured by Lowry et al. (1951) method using bovine serum
albumin as a standard, as previously described by Frey et al.
(2006).
2.6. Step-down inhibitory avoidance apparatus and procedures
Ten days after pneumococcal meningitis the animals that
received the extended treatment for 9 days with CBD were used
for memory evaluation. The step-down inhibitory avoidance task
was carried out in the apparatus with a 502525 cm acrylic
box with the ﬂoor consisting of parallel caliber stainless steel bars
(1 mm diameter) spaced 1 cm apart. A 7 cm-wide by 2.5 cm-high
platform was placed on the ﬂoor of the box against the left wall
(Quevedo et al., 1999; Roesler et al., 2003). In the training trial,
the animals were placed on the platform and their latency to step
down on the grid with all four paws was measured with an
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the animals received a 0.4 mA, 2.0 s foot shock. A retention test
trial was performed 24 h after training. The retention test trial
was procedurally identical to training, except that no foot shock
was performed. Immediately after the behavioral test, the rats
were killed and the hippocampus and pre-frontal cortex were
removed and stored at 80 1C (Izquierdo et al., 1998).Sham Non-treatment CBD 2.5 CBD 5 CBD 10
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)2.7. Statistics
The results were shown by mean7S.E.M. of 5–6 and 10
animals for acute and extended treatments in each sub-group.
Differences among groups were evaluated by using analysis of
variance (ANOVA) followed by Tukey post-hoc test. Data for
inhibitory avoidance are presented as the median (interquartile
range) of retention test latencies. Differences between training
and test session latencies within each group were determined
using the Wilcoxon test. Comparisons among groups were per-
formed using Mann–Whitney U test. P values o0.05 were
considered statistically signiﬁcant.Sham Non-treatment CBD 2.5 CBD 5 CBD 10
Meningitis
Fig. 2. Kinetics of IL-1b levels in hippocampus and frontal cortex 6 h after
meningitis induction by S. pneumoniae. The concentrations of IL-1b levels in
hippocampus (A) and frontal cortex (B) were obtained 6 h after meningitis
induction. Levels of cytokines/chemokine were assessed by ELISA and results are
shown as pg of cytokine/chemokine per 100 mg of tissue. Results show the
mean7S.E.M. of 5–6 animals in each group. Symbols indicate statistically
signiﬁcant when compared with sham group nPo0.05.3. Results
3.1. Acute treatment
We evaluated BDNF, TNF-a, IL-1b, IL-6 and CINC-1 levels at 6 h
after pneumococcal meningitis induction in different groups;
sham; meningitis; meningitisþCBD 2.5 mg/kg; meningitisþCBD
5 mg/kg and meningitisþCBD10 mg/kg.
Fig. 1A and B shows the TNF-a level in the hippocampus and
frontal cortex. We veriﬁed an increased level of TNF-a in the
hippocampus and frontal cortex, however the CBD treatment did
not revert these ﬁndings.Sham Non-treatment CBD 2.5 CBD 5 CBD 10
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Fig. 1. Kinetics of TNF-a levels in hippocampus and frontal cortex 6 h after
meningitis induction by S. pneumoniae. The concentrations of TNF-a levels in
hippocampus (A) and frontal cortex (B) were obtained 6 h after meningitis
induction. Levels of cytokines/chemokine were assessed by ELISA and results are
shown as pg of cytokine/chemokine per 100 mg of tissue. Results show the
mean7S.E.M. of 5–6 animals in each group. Symbols indicate statistically
signiﬁcant when compared with sham group nPo0.05.Figs. 2 and 3 show the IL-1b and IL-6, respectively. The CBD
treatment did not alter the IL-1b and IL-6 levels in the hippo-
campus (Figs. 2A and 3A) and in frontal cortex (Figs. 2B and 3B).
Fig. 4A and B shows the CINC-1 levels in hippocampus and
frontal cortex. In Fig. 4, the CINC-1 levels increased in both
structures during the meningitis, however the CDB treatment
did not revert these levels.
Finally, we analyzed the BDNF levels (Fig. 5A and B) in the
hippocampus and frontal cortex. The meningitis process and the
CBD treatment did not alter the BDNF levels in both structures.
3.2. Chronic treatment
In Fig. 6A and B we demonstrate the TNF-a level in the
hippocampus and in frontal cortex. We can observe that menin-
gitis did not change the TNF-a level in hippocampus 10 days after
meningitis induction Fig. 6A. However, in the frontal cortex
Fig. 6B the TNF-a levels increased after meningitis induction
and CBD treatment with 2.5, 5 and 10 mg/kg decrease the high
levels when compared with meningitis group without treatment
(Po0.05). Fig. 7A and B shows the BDNF levels in hippocampus
and frontal cortex. The meningitis group without treatment
decreases the BDNF level in frontal cortex (Po0.05) Fig. 7B.
However, Fig. 7B shows that there was no change in hippocam-
pus. We can observe that CBD treatment in all doses increase the
BDNF levels when compared with meningitis group without
treatment (Po0.05).
In the inhibitory avoidance test (Fig. 8), there was no difference
between training session between groups. In the training and test
sessions there were not statistical differences between meningitis,
meningitisþCBD 2.5 mg/kg and meningitisþCBD 5 mg/kg, show-
ing memory impairment in these groups. Nevertheless, the
extended treatment with CBDþ10 mg/kg prevented memory
impairment when compared to meningitis group in the training
session (Po0.05).
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Fig. 3. Kinetics of IL-6 levels in hippocampus and frontal cortex 6 h after
meningitis induction by S. pneumoniae. The concentrations of IL-6 levels in
hippocampus (A) and frontal cortex (B) were obtained 6 h after meningitis
induction. Levels of cytokines/chemokine were assessed by ELISA and results are
shown as pg of cytokine/chemokine per 100 mg of tissue. Results show the
mean7S.E.M. of 5–6 animals in each group. Symbols indicate statistically
signiﬁcant when compared with sham group nPo0.05.
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Fig. 4. Kinetics of CINC-1 levels in hippocampus and frontal cortex 6 h after
meningitis induction by S. pneumoniae. The concentrations of CINC-1 levels in
hippocampus (A) and frontal cortex (B) were obtained 6 h after meningitis
induction. Levels of cytokines/chemokine were assessed by ELISA and results are
shown as pg of cytokine/chemokine per 100 mg of tissue. Results show the
mean7S.E.M. of 5–6 animals in each group. Symbols indicate statistically
signiﬁcant when compared with sham group nPo0.05.
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Fig. 5. Kinetics of BDNF levels in hippocampus and frontal cortex 6 h after
meningitis induction by S. pneumoniae. The concentrations of BDNF levels in
hippocampus (A) and frontal cortex (B) were obtained 6 h after meningitis
induction. Levels of BDNF were assessed by ELISA and results are shown as pg
of BDNF per 100 mg of tissue. Results show the mean7S.E.M. of 5–6 animals in
each group. ‘**’ Symbols indicate statistically signiﬁcant when compared with
sham group nnPo0.05.
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Fig. 6. Kinetics of TNF-a levels in hippocampus and frontal cortex 10 days after
meningitis induction by S. pneumoniae. The concentrations of TNF-a levels in
hippocampus (A) and frontal cortex (B) were obtained 10 days after meningitis
induction. Levels of cytokines/chemokine were assessed by ELISA and results are
shown as pg of BDNF per 100 mg of tissue. Results show the mean7S.E.M. of 5–6
animals in each group. ‘*’ Symbol indicates statistically signiﬁcant when compared
with sham group nPo0.05. ‘**’ Symbols indicate statistically signiﬁcant when
compared with meningitis group without treatment nnPo0.05.
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Despite signiﬁcant advances in pneumococcal meningitis
treatment, it remains one of the most important worldwide
infectious diseases and it is still associated with high mortalityand morbidity. In addition, many survivors present permanent
neurological sequelae (Sellner et al., 2010; Mook-Kanamori et al.,
2011). In the present study, we investigated the effects of acute
and extended adjuvant treatment with CBD on pro-inﬂammatory
cytokines and aversive memory.
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Fig. 7. Kinetics of BDNF levels in hippocampus and frontal cortex 10 days after
meningitis induction by S. pneumoniae. The concentrations of BDNF levels in
hippocampus (A) and frontal cortex (B) were obtained 10 days after meningitis
induction. Levels of cytokines/chemokine were assessed by ELISA and results are
shown as pg of BDNF per 100 mg of tissue. Results show the mean7S.E.M. of 5–6
animals in each group. ‘*’ Symbol indicates statistically signiﬁcant when compared
with sham group nPo0.05.
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Fig. 8. Inhibitory avoidance test 10 days after induction of meningitis by
S. pneumoniae. Data from the step-down inhibitory avoidance are presented as
median and interquartile ranges, n¼10 rats per group nPo0.05 versus training.
Comparisons among groups were performed using Mann–Whitney U tests. Within
individual groups it was analyzed by Wilcoxon test.
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an increase in the levels of TNF-a and CINC-1 in hippocampus and
frontal cortex. However, the administration of different doses of
CBD did not reverse these levels in the hippocampus and frontal
cortex. In previous studies, using the same rat model of meningi-
tis, we veriﬁed the increase of TNF-a and CINC-1 levels in
hippocampus and frontal cortex at 6 h after pneumococcal
meningitis induction (Barichello et al., 2010a). Furthermore, in
jugular plasma, the CINC-1 increased at 3 h staying elevated up to
6 h and TNF-a levels increased at 6 h. In arterial plasma we
veriﬁed the increased of the CINC-1 at 6 h after induction,
indicating that possibly CINC-1 and TNF-a are produced in the
CNS (Barichello et al., 2012). TNF-a, IL-1b and IL-6 are produced
in the early response after pneumococcal meningitis induction(Ta¨uber and Moser, 1999). TNF-a and CINC-1 are also implicated
in the inﬁltration of inﬂammatory cells into the brain parenchyma
(Saukkonen et al., 1990; Katayama et al., 2009). Moreover, such
indeterminate properties, prosperous actions and the exact site at
which CBD could exert its neuroinﬂammatory and neuroprotec-
tive effects are still not completely elucidated. The recently
discovered ability of different cannabinoids, including CBD, to
display an extra-cannabinoid receptor binding activity has been
highlighted by the observation that these compounds may go
nuclear to exert their activity through the interaction with
peroxisome proliferator-activated receptors (PPARs) (O’Sullivan
et al., 2007). Furthermore, in the concentration 10 mg/kg of the
CDB administered for 15 days reduced Ab-induced neuroinﬂam-
mation and promoted hippocampal neurogenesis through PPARs
(Esposito et al., 2011). In a previous study we veriﬁed that
pneumococcal meningitis also cause change of the mitochondrial
respiratory chain (Barichello et al., 2010b) and oxidative stress
(Barichello et al., 2010c). Furthermore, apoptosis in pneumococcal
meningitis is correlated with production of the oxygen reactive
species that causes mitochondrial dysfunction that leads to the
release of the apoptosis-inducing factor into the cytosol (Mitchell
et al., 2004).
Independent from classical CB1/2 receptors, the CBD (3 and
10 mg/kg) 2 h before of the hepatic ischemia reperfusion reduced
the extent of liver inﬂammation, oxidative/nitrative stress and
cell death (Mukhopadhyay et al., 2011). Hepatic ischemia reper-
fusion also leads to an early impairment of the activities of the
enzymes of the mitochondrial respiratory chain, mitochondrial
dysfunction, allowing more reactive oxygen species to leak out of
the respiratory chain (Jaeschke et al., 2003; Moon et al., 2008).
CBD likewise was reported to blunt t hyperphosphorylation in
cultured neurons by reducing phosphorylation of glycogen
synthase kinase 3b (GSK3b), acting as a Wnt/b-catenin pathway
rescuer, although alternative mechanisms may be implicated in
inducing this effect (Esposito et al., 2006). GSK 3b is involved in
toll-like receptor signaling and regulates the production of pro-
inﬂammatory cytokines and septic shock (Woodgett and Ohashi,
2005). In another study, the chronic administration of CBD at
different doses (2.5, 5, and 10 mg/kg, i.p., by seven days) also
prevented memory impairment of rats 10 days after to sepsis by
cecal ligation and perforation (Cassol-Jr et al., 2010).
Furthermore, CDB decreased TNF-a, IL-6 and chemokines
(MCP-1 and MIP-2) in a murine model of acute lung injury
(Ribeiro et al., 2012); synthetic cannabinoid inhibited TNF-a,
IL-1b and IL-6 expression induced by lipopolysaccharide in rat
cerebellar granule cells (Chiba et al., 2011). CBD reduced blood
brain-barrier alterations and prevented endothelial inﬂammatory
response in arteriolar and venular vasodilation, induced by
lipopolysaccharide (Ruiz-Valdepen˜as et al., 2011). In a previous
study we reported the increase of the TNF-a level in frontal cortex
10 days after meningitis induction (Barichello et al., 2010d).
In this study, we observed in animals that received prolonged
treatment with CDB decreased the TNF-a level in frontal cortex 10
days after meningitis induction. Furthermore, we evaluated the
aversive memory with extended CBD treatment in different
concentrations 2.5, 5 and 10 mg/kg, however, only the highest
CBD dose prevented memory impairment. CDB in the same
concentrations also prevented this impairment in rats submitted
to sepsis (Cassol-Jr et al., 2010).
It has been well established that pneumococcal meningitis
survivors present long-term cognitive impairment. We have
already demonstrated that rats who survived pneumococcal
meningitis presented learning and memory impairment 10 days
after meningitis induction (Barichello et al., 2010e). S. pneumoniae
replication within the subarachnoid space initiates a complex
host immune response (Sellner et al., 2010), furthermore,
T. Barichello et al. / European Journal of Pharmacology 697 (2012) 158–164 163lipoteichoic acid and peptidoglycans are recognized by TLR-2 and
pneumolysin by TLR-4 receptors presenting in antigen-presenting
cells (Mook-Kanamori et al., 2011). When they are activated they
induce the establishment of nuclear factor kappa B (NF-kB) (Opitz
et al., 2009). It is also a transcriptional activator of many genes
involved in the pathogenesis of pneumococcal meningitis, such
as, TNF-a, IL-1b, nitric oxide synthase and intercellular adhesion
molecules (Koedel et al., 2000; Kastenbauer et al., 2004). Some
studies indicate that CBD exerts its anti-inﬂammatory effects
through NF-kB inhibition. For instance, CBD treatment inhibited
the NF-kB-dependent mRNA and TNF-a, in diabetic myocardial
tissues (Rajesh et al., 2010). CBD also reduced IL-1b, IL-6 and IFN-
b and the activity of the NF-kB pathway, a primary pathway
regulating the expression of pro-inﬂammatory genes from
lipopolysaccharide-activated in microbial cells (Kozela et al., 2010).
Nevertheless, new adjunctive therapies are needed to improve
the prognosis of bacterial meningitis (Mook-Kanamori et al., 2011).
Although descriptive, our results demonstrate that chronic treat-
ment with CBD plays an anti-inﬂammatory role in pneumococcal
meningitis. Furthermore, it prevents cognitive damage, possibly
representing a new pharmacological approach towards pneumo-
coccal meningitis. Future studies must be realized to understand
the underlying mechanisms.Acknowledgments
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